---
title: "PMGC rises 2% as unit plans EL-22 antigen study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292350804.md"
description: "PMGC climbs 2% during regular trading. Subsidiary NorthStrive to study EL-22 antigen expression."
datetime: "2026-07-10T19:01:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292350804.md)
  - [en](https://longbridge.com/en/news/292350804.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292350804.md)
generator: "portal-rs"
---

# PMGC rises 2% as unit plans EL-22 antigen study

PMGC(ELAB.US) 盘中涨 1.89%，现报 1.08 美元。

消息面上，公司子公司 NorthStrive 计划进行独立流式细胞术研究以量化工程化乳酸乳球菌上的 EL-22 抗原表达。该股 7 月 10 日曾一度大涨 29%，成交量达 3167 万股，随后有所回落。

### Related Stocks

- [ELAB.US](https://longbridge.com/en/quote/ELAB.US.md)

## Related News & Research

- [PMGC unit A&B Aerospace signs long-term supply agreement with PAD Group](https://longbridge.com/en/news/294060161.md)
- [PMGC unit NorthStrive to launch independent FACS study to quantify EL-22 antigen expression](https://longbridge.com/en/news/292316283.md)
- [PMGC unit NorthStrive signs exclusive FSU license to develop multi-domain drone payload technology](https://longbridge.com/en/news/292481384.md)
- [PMGC Holdings Subsidiary Secures Exclusive License for Aerospace and Defense Patent 12,291,334](https://longbridge.com/en/news/291979789.md)
- [PMGC unit NorthStrive Biosciences files two US patent applications for muscle preservation in GLP-1 weight loss market](https://longbridge.com/en/news/290190535.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**